Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cantor & Nissel is a specialized manufacturer of contact lenses and ocular prosthetics, now operating as a subsidiary of CooperVision following its acquisition in 2022. Based in the United Kingdom, the company is globally renowned for its expertise in custom-made lenses, particularly hand-painted prosthetic lenses used to treat ocular disfigurements and congenital defects. Their product portfolio includes a wide range of rigid gas permeable (RGP) and soft lenses designed for complex conditions such as keratoconus, aniridia, and irregular corneas. By combining traditional craftsmanship with modern manufacturing technology, Cantor & Nissel provides critical optical and aesthetic solutions to practitioners and hospitals worldwide. The company maintains a strong focus on niche ophthalmic requirements, offering bespoke designs that are not available through mass-market manufacturers. Their facility in Brackley serves as a hub for high-precision lens lathing and artistic hand-painting, ensuring high-quality outcomes for patients with unique visual needs.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cantor & Nissel.